First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

March 2, 2022

Study Completion Date

June 25, 2022

Conditions
Diabetic Macular Edema
Interventions
DRUG

CU06-1004, Single dose

"Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)*~*Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5"

DRUG

CU06-1004, Multiple doses

"Multiple doses of CU06-1004, 7 days, 3 dose levels*, oral capsule~*The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD"

DRUG

Placebo

Placebo matched to CU06-1004, oral capsule

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

KCRN Research, LLC

INDUSTRY

lead

Curacle Co., Ltd.

INDUSTRY

NCT04795037 - First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers | Biotech Hunter | Biotech Hunter